[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345340-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345340-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","exosomal-non-coding-rnas-in-gastrointestinal-cancer-drug-resistance-a-systematic-review-of-emerging-mechanisms-and-clinical-implications","Exosomal Non-Coding RNAs in Gastrointestinal Cancer Drug Resistance - A Systematic Review of Emerging Mechanisms and Clinical Implications","","Gastrointestinal (GI) tumours are among the most prevalent cancers worldwide, and tumour drug resistance is a major driver of chemotherapy failure and poor patient outcomes. Exosomes and noncoding RNAs from tumour cells, including microRNAs, long noncoding RNAs and circular RNAs, are linked to GI carcinogenesis and resistance development. A systematic review under PRISMA examined PubMed, Web of Science, Scopus and Google Scholar and included 76 studies (1994–2025). The review identifies exosomal ncRNAs with prognostic and predictive value, yet their clinical translation remains early due to limitations in validation, standardisation and specificity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/exosomal-non-coding-rnas-in-gastrointestinal-cancer-drug-resistance-a-systematic-review-of-emerging-mechanisms-and-clinical-implications/345340/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/exosomal-non-coding-rnas-in-gastrointestinal-cancer-drug-resistance-a-systematic-review-of-emerging-mechanisms-and-clinical-implications/345340.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-09","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does tumour drug resistance play in gastrointestinal cancer treatment outcomes?","Question",{"text":63,"@type":64},"Tumour drug resistance is presented as the main reason for failure of drug treatment, undermining chemotherapy efficacy and contributing to poor patient outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which types of non-coding RNAs are discussed in relation to exosomal biomarkers?",{"text":68,"@type":64},"The review highlights microRNAs, long non-coding RNAs, and circular RNAs originating from tumour cells as being associated with GI drug resistance and disease development.",{"name":70,"@type":61,"acceptedAnswer":71},"How was the systematic review conducted and how many studies were included?",{"text":72,"@type":64},"The review followed PRISMA guidelines and searched PubMed, Web of Science, Scopus and Google Scholar. Seventy-six studies were included: 50 cohort studies and 26 nested case–control studies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345340,1790614089,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Journal of Cellular and Molecular Medicine  \nREVIEW  OPEN ACCESS   \nExosomal Non-Coding RNAs in Gastrointestinal Cancer Drug Resistance: A Systematic Review of Emerging Mechanisms and Clinical Implications  \nMohsen Sharif-zak1  | Zahra Sadeghloo2 | Fateme Binayi1 | Stefania Nobili3 | Sara Ashtari1  | Amir Sadeghi1  | Nayeralsadat Fatemi2   \n1Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran | 2Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran | 3Department of Neuroscience, Psychology, Drug Research and Child Health – NEUROFARBA – Pharmacology and Toxicology Section, University of Florence, Firenze, Italy  \nCorrespondence: Nayeralsadat Fatemi ([n_fatemi_1363@yahoo.com](n_fatemi_1363@yahoo.com); [n.fatemi@sbmu.ac.ir](n.fatemi@sbmu.ac.ir))  \nReceived: 16 July 2025 | Revised: 4 November 2025 | Accepted: 14 March 2026  \nKeywords: drug resistance | exosomes | gastrointestinal neoplasms | neoplasm | RNA | untranslated  \nABSTRACT  \nGastrointestinal (GI) tumours are one of the most prevalent cancers globally. Even with normal GI function, individuals may develop neoplasms, highlighting the need to better understand the underlying causes of tumorigenesis. The emergence of tumour drug resistance represents the main reason for the failure of drug treatment; thus, it is imperative to investigate all the potential mechanisms of this very complex phenomenon. It is significant that exosomes and noncoding RNAs, such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), originating from tumour cells, are linked to both GI drug resistance and the carcinogenesis and development of GI disease. Thus, we propose a systematic review of the literature to provide an overview of the current landscape concerning exosomal ncRNAs as diagnostic and prognostic biomarker resources in resistant GI cancer. We performed the current systematic review according to PRISMA guidelines and comprehensively explored PubMed, Web of Science, Scopus and Google Scholar databases to achieve the article search. Seventy-six studies were included in the investigation, comprising 50 cohort studies and 26 nested case–control studies (between 1994 and 2025). Among all systematically reviewed exosomal ncRNAs, we primarily found molecules with prognostic significance and predictive relevance, and those that serve both purposes have been identified. Furthermore, among all analysed ncRNAs isolated from exosomes, miRNAs, lncRNAs and circRNAs have emerged as the most extensively studied and are proposed as potential tools for predicting resistance or sensitivity to GI cancer treatments. Our analysis offers a comprehensive overview of the current landscape concerning exosomal ncRNAs as potential clinical biomarkers for resistant GI tumours. However, despite extensive research efforts, the application of exosomal biomarkers in GI cancers is still in its infancy. None of the identified exosomal biomarkers have advanced beyond preclinical studies, and their applicability in clinical settings remains limited, largely due to challenges in clinical validation, standardisation and biomarker specificity.  \n1 | Introduction  \nThe efficacy of chemotherapy, the cornerstone of treatment for metastatic gastrointestinal (GI) cancers, is profoundly  \nundermined by the pervasive challenge of drug resistance, which represents the principal driver of treatment failure and poor patient outcomes. Chemotherapy is the primary treatment for GI tumours that have metastasised [1, 2] . Surgery is in fact  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 ","cbCaisAg8lAIpPAn","https://ap.wps.com/l/cbCaisAg8lAIpPAn","pdf",3672067,35,"English","# Introduction\n# Exosomes and non-coding RNAs in GI cancer drug resistance\n# Systematic review methods (PRISMA)\n# Included studies and ncRNA categories\n# Prognostic and predictive biomarkers\n# Clinical translation challenges","[{\"question\":\"What role does tumour drug resistance play in gastrointestinal cancer treatment outcomes?\",\"answer\":\"Tumour drug resistance is presented as the main reason for failure of drug treatment, undermining chemotherapy efficacy and contributing to poor patient outcomes.\"},{\"question\":\"Which types of non-coding RNAs are discussed in relation to exosomal biomarkers?\",\"answer\":\"The review highlights microRNAs, long non-coding RNAs, and circular RNAs originating from tumour cells as being associated with GI drug resistance and disease development.\"},{\"question\":\"How was the systematic review conducted and how many studies were included?\",\"answer\":\"The review followed PRISMA guidelines and searched PubMed, Web of Science, Scopus and Google Scholar. Seventy-six studies were included: 50 cohort studies and 26 nested case–control studies.\"}]","Exosomal Non-Coding RNAs in Gastrointestinal Cancer Drug Resistance - A Systematic Review of Emerging Mechanisms and Clinical Implications | PDF",1790057363,88,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/674330265bf4fbe8ccd6f1c2e0417f2e.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10bcb319e9806fe2762b3cb9e7a31ef4.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1be21b12b1ea9fe25b9c3ce6c8cfb61a.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a432a7c1ab463b546ad8f7d45384924.webp",980,1287]